Get the Stockscreener App
10.96
1.79%
-0.20
After Hours:
10.96
Replimune Group Inc stock is traded at $10.96, with a volume of 806.34K.
It is down -1.79% in the last 24 hours and up +7.77% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$11.16
Open:
$11.06
24h Volume:
806.34K
Relative Volume:
1.19
Market Cap:
$745.39M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-3.6902
EPS:
-2.97
Net Cash Flow:
$-176.27M
1W Performance:
+0.00%
1M Performance:
+7.77%
6M Performance:
+34.15%
1Y Performance:
-35.94%
1-Day Range:
$10.71
$11.42
1-Week Range:
$10.71
$11.59
52-Week Range:
$4.92
$17.01
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Analytical Overview: Replimune Group Inc (REPL)’s Ratios Tell a Financial Story - The Dwinnex
Replimune Group Inc (REPL) expanding its growth trajectory ahead - SETE News
Replimune Group's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Point72 DIFC Ltd Makes New $57,000 Investment in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Deerfield Management Company L.P. Series C Has $264,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
An analyst sees good growth prospects for Replimune Group Inc (REPL) - SETE News
Point72 Asia Singapore Pte. Ltd. Makes New $443,000 Investment in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat
Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex
JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $17.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Given New $17.00 Price Target at JPMorgan Chase & Co. - Defense World
A stock that deserves closer examination: Replimune Group Inc (REPL) - US Post News
Rhumbline Advisers Buys 5,732 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Analysts - Defense World
Chief Financial Officer Hill Emily Luisa sale 8,938 shares of Replimune Group Inc [REPL] - Knox Daily
Replimune Group (NASDAQ:REPL) Shares Gap Up to $11.03 - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by Bank of New York Mellon Corp - Defense World
Arizona State Retirement System Takes Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Shares Down 6.4% - Defense World
Its Stock Has Paid Off Big Time For Replimune Group Inc - SETE News
Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright - Defense World
Replimune Group (NASDAQ:REPL) Shares Gap Up to $11.03 - MarketBeat
Are Replimune Group Inc’shares a good deal? - US Post News
Analytical Lens: Exploring Replimune Group Inc (REPL)’s Financial Story Through Ratios - The Dwinnex
Quest Partners LLC Acquires 3,150 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Down 6.4% - MarketBeat
Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright - MarketBeat
Taking a Closer Look At Replimune Group Inc (REPL) Following Its Recent Trade - Knox Daily
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - StockTitan
Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by Acadian Asset Management LLC - MarketBeat
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - ForexTV.com
Acadian Asset Management LLC Buys 71,867 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by TD Asset Management Inc - Defense World
Los Angeles Capital Management LLC Has $646,000 Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 7.4% - MarketBeat
Q2 2025 Earnings Forecast for Replimune Group, Inc. Issued By HC Wainwright (NASDAQ:REPL) - MarketBeat
Financial Snapshot: Analyzing Replimune Group Inc (REPL)’s Key Ratio Metrics - The Dwinnex
Replimune Group (NASDAQ:REPL) Given Buy Rating at HC Wainwright - Defense World
Zurcher Kantonalbank Zurich Cantonalbank Sells 3,497 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Objective long/short (REPL) Report - Stock Traders Daily
ROTH MKM analysts initates a Buy rating for Replimune Group Inc (REPL) - Knox Daily
H.C. Wainwright maintains Buy rating on Replimune shares after FDA meeting - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
What was Replimune Group Inc (REPL)’s performance in the last session? - US Post News
MA Biotech Reports Positive Meeting with FDA - Streetwise Reports
Replimune stock target, buy rating maintained on positive FDA pre-BLA meeting - Investing.com Canada
Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 - StockTitan
Replimune Group announces results of annual stockholder meeting - Investing.com
Signaturefd LLC Cuts Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group announces results of annual stockholder meeting - Investing.com India
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):